Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their one-month progress using Minoxidil and RU58841 for hair loss, noting significant shedding after micro-needling and seeking opinions on their regrowth. They stopped micro-needling and added RU58841 to their treatment.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A user has been using minoxidil without noticing improvements and is considering adding tretinoin gel to their regimen before trying RU58841. They seek advice on how to mix and apply tretinoin with minoxidil, including concentration and application frequency.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Hair cloning by Tsuji has not had recent updates. Users discuss using Minoxidil, finasteride, and RU58841 for hair loss.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

9 Month Update: Topical Fin/Min (0.3%, 6%), Weekly Microneedle 1.5mm, 40 Years Old. User shares progress pictures and discusses hair loss treatments used.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

A user shared their 88-day progress using 1.25mg finasteride, topical minoxidil, and weekly 1mm microneedling, noting improvement from NW 4.5 to around NW 3. Another user complimented the progress.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.

RU58841 from AliExpress and its legitimacy. Users discuss purchasing RU58841 from different sources and the effectiveness of the product.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.